Long-term exposure to duodenal levodopa/carbidopa infusion therapy improves quality of life in relation especially to mobility, activities of daily living, and emotional well-being

Acta Neurologica Scandinavica

Volumn 125, Issue 3, 2012, Pages 187-191

  Santos Garcia D ^a   Sanjurjo, L F ^a   MacIas M ^a   Llaneza, M ^a   Carpintero, P ^a   de la Fuente Fernandez R ^a  

^a Universidad de La Coruña   (Spain)

Author keywords

Activities of daily living; Duodenal levodopa infusion; Mobility; Motor complications; Parkinson s disease; Quality of life

Indexed keywords

CARBIDOPA PLUS LEVODOPA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COGNITION; CONTINUOUS INFUSION; DAILY LIFE ACTIVITY; FEMALE; FOLLOW UP; HUMAN; INTERPERSONAL COMMUNICATION; MALE; PARKINSON DISEASE; PHYSICAL MOBILITY; QUALITY OF LIFE; SOCIAL SUPPORT; WELLBEING;

ACTIVITIES OF DAILY LIVING; AGED; ANTIPARKINSON AGENTS; CARBIDOPA; DRUG ADMINISTRATION SCHEDULE; EMOTIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; PROSPECTIVE STUDIES; QUALITY OF LIFE; TIME;

EID: 84856607672     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2011.01523.x     Document Type: Article

References (14)

1. Nyholm D, Nilsson Remahl AI, Dizdar N et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 2005;64:216-23.
2. Antonini A, Isaias IU, Canesi M et al. Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome. Mov Disord 2007;22:1145-9.
3. Puente V, De Fabregues O, Oliveras C et al. Eighteen month study of continuous intraduodenal levodopa infusion in patients with advanced Parkinson's disease: impact on control of fluctuations and quality of life. Parkinsonism Relat Disord 2010;16:218-21.
4. Honig H, Antonini A, Martinez-Martin P et al. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord 2009;24:1468-74.
5. Antonini A, Mancini F, Canesi M et al. Duodenal levodopa infusion improves quality of life in advanced Parkinson's disease. Neurodegener Dis 2008;5:244-6.
6. Nyholm D, Constantinescu R, Holmberg B, Dizdar N, Askmark H. Comparison of apomorphine and levodopa infusions in four patients with Parkinson's disease with symptom fluctuations. Acta Neurol Scand 2009;119:345-8.
7. Santos-García D, Macias M, Llaneza M, Aneiros A. Suicide following duodenal levodopa infusion for Parkinson′s disease. Mov Disord 2009;24:2029-30.
8. Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N. The Parkinson′s Disease Questionnaire (PDQ-39): development and validation of a Parkinson′s disease summary index score. Age Ageing 1997;26:353-7.
9. Westin J, Nyholm D, Groth T, Dougherty MS, Yerramsetty PK, Palhagen SE. Outcome prediction of enteral levodopa/carbidopa infusion in advanced Parkinson's disease. Parkinsonism Relat Disord 2006;12:509-13.
10. Odin P, Wolters E, Antonini A. Continuous dopaminergic stimulation achieved by duodenal levodopa infusion. Neurol Sci 2008;29:S387-8.
11. Santos-García D, Macías M, Llaneza M et al. Experience with continuous levodopa enteral infusion (Duodopa(®)) in patients with advanced Parkinson's disease in a secondary level hospital. Neurología 2010;25:536-43.
12. Isacson D, Bingefors K, Kristiansen IS, Nyholm D. Fluctuating functions related to quality of life in advanced Parkinson′s disease: effects of duodenal levodopa infusion. Acta Neurol Scand 2008;118:379-86.
13. Annic A, Devos D, Segury D, Dujardin K, Destée A, Defebvre L. Continuous dopaminergic stimulation by duodopa in advanced Parkinson′s disease: efficacy and safety. Rev Neurol (Paris) 2009;165:718-27.
14. Sławek J, Derejko M, Lass P. Factors affecting the quality of life of patients with idiopathic Parkinson's disease - a cross-sectional study in an outpatient clinic attendees. Parkinsonism Relat Disord 2005;11:465-8.